WO2009100513A3 - Peptideo des-[asp1hala1]- agonista da angiotensina-(1 -7) e composiҫões farmacêuticas para tratamento de doenças - Google Patents

Peptideo des-[asp1hala1]- agonista da angiotensina-(1 -7) e composiҫões farmacêuticas para tratamento de doenças Download PDF

Info

Publication number
WO2009100513A3
WO2009100513A3 PCT/BR2009/000046 BR2009000046W WO2009100513A3 WO 2009100513 A3 WO2009100513 A3 WO 2009100513A3 BR 2009000046 W BR2009000046 W BR 2009000046W WO 2009100513 A3 WO2009100513 A3 WO 2009100513A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
ala1
asp1
agonist
treatment
Prior art date
Application number
PCT/BR2009/000046
Other languages
English (en)
French (fr)
Other versions
WO2009100513A2 (pt
Inventor
Robson Augusto Souza Dos Santos
Anderson José FERREIRA
Rubén Dario SINISTERRA
Original Assignee
Universidade Federal De Minas Gerais - Ufmg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal De Minas Gerais - Ufmg filed Critical Universidade Federal De Minas Gerais - Ufmg
Priority to CN2009801089471A priority Critical patent/CN102124023A/zh
Priority to EP09841273.7A priority patent/EP2264048B1/en
Priority to US12/867,599 priority patent/US9974825B2/en
Publication of WO2009100513A2 publication Critical patent/WO2009100513A2/pt
Publication of WO2009100513A3 publication Critical patent/WO2009100513A3/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A presente invenção relaciona-se ao uso do peptídio Des-[Asp1]-[Ala1]- Angiotensina-(1-7) (Ala1-Arg2-Val3-Tyr4-Ile5-His6-Pro7) e/ou compostos relacionados como agentes vasculoprotetores e cardioprotetores em mamíferos. A invenção compreende ainda a obtenção de composições contendo Des-[Asp1]-[Ala1]-Angiotensina-(1-7) e/ou compostos relacionados e seu uso em métodos para tratamento ou prevenção de doenças.
PCT/BR2009/000046 2008-02-13 2009-02-13 Peptideo des-[asp1hala1]- agonista da angiotensina-(1 -7) e composiҫões farmacêuticas para tratamento de doenças WO2009100513A2 (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN2009801089471A CN102124023A (zh) 2008-02-13 2009-02-13 用于疾病治疗的肽Des-[ASP1]-[ALA1],血管紧张素-(1-7)激动剂和药物组合物
EP09841273.7A EP2264048B1 (en) 2008-02-13 2009-02-13 Peptide des-[asp1]-[ala1],angiotensin-(1-7) agonist and pharmaceutical compounds for the treatment of diseases
US12/867,599 US9974825B2 (en) 2008-02-13 2009-02-13 Peptides Des-[Asp1]-[Ala1], angiotensin-(1-7) agonist and pharmaceutical compositions for the treatment of diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0800585A BRPI0800585B8 (pt) 2008-02-13 2008-02-13 composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
BRPI0800585-0 2008-02-13

Publications (2)

Publication Number Publication Date
WO2009100513A2 WO2009100513A2 (pt) 2009-08-20
WO2009100513A3 true WO2009100513A3 (pt) 2009-11-05

Family

ID=40957305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2009/000046 WO2009100513A2 (pt) 2008-02-13 2009-02-13 Peptideo des-[asp1hala1]- agonista da angiotensina-(1 -7) e composiҫões farmacêuticas para tratamento de doenças

Country Status (5)

Country Link
US (1) US9974825B2 (pt)
EP (1) EP2264048B1 (pt)
CN (1) CN102124023A (pt)
BR (1) BRPI0800585B8 (pt)
WO (1) WO2009100513A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0800585B8 (pt) 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
EP2455388A1 (en) * 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
BRPI1103387B1 (pt) * 2011-07-21 2022-04-19 Universidade Federal De Minas Gerais Composição farmacêutica para tratamento de hipertensão arterial baseada na co- administração de anti-hiperstensivos e angiotensina (1-7) ou outro agonista do receptor mas
BR102013023224B1 (pt) * 2012-09-14 2023-02-07 Universidade Federal De Minas Gerais PEPTÍDEO (ARGº)N-ANGIOTENSINA-(1-7) E COMPOSIÇÕES FARMACÊUTICAS PARA TRATAMENTO DE DOENÇAS
CA2884792A1 (en) * 2012-09-17 2014-03-20 Tarix Pharmaceuticals Ltd. Oral formulations of angiotensin
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
WO2014078929A1 (pt) * 2012-11-26 2014-05-30 Universidade Federal De Minas Gerais - Ufmg Formulações tópicas para a prevenção e tratamento da alopecia e para inibição do crescimento de pêlos
JP2016520592A (ja) 2013-05-24 2016-07-14 タリックス ファーマシューティカルズ リミテッド マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド
WO2015058214A1 (en) 2013-10-18 2015-04-23 Trustees Of The University Of Pennsylvania Oral delivery of angiotensin converting enzyme 2 (ace2) or angiotensin-(1-7) bioencapsulated in plant cells
AU2015294371B2 (en) 2014-07-21 2018-02-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
WO2018129506A2 (en) * 2017-01-09 2018-07-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang (1-7) derviative oligopeptides for the treatment of pain
EP3350200A4 (en) 2015-09-18 2019-03-27 Wake Forest University Health Services ANGIOTENSIN ANALOGUES (1-7) AND ASSOCIATED METHODS
JP2018530590A (ja) 2015-10-14 2018-10-18 タリックス ファーマシューティカルズ リミテッド 表皮水疱症の処置のための方法及び組成物
WO2018165495A1 (en) * 2017-03-10 2018-09-13 Gaffney Kevin J Cyclodextrin-nle3-a(1-7) compositions and their use
EP3820498A1 (en) * 2018-06-14 2021-05-19 University College Cork-National University of Ireland Cork Peptide for disease treatment
EP4371556A1 (en) 2022-11-15 2024-05-22 Explicat Pharma GmbH Angiotensin(1-7) pharmaceutical compositions for inhalation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
JP4911854B2 (ja) * 2000-04-13 2012-04-04 ナショナル ユニヴァーシティー オブ シンガポール 腎臓関連の疾患の治療薬および／または予防薬、並びにデス−アスパラギン酸塩−アンジオテンシンｉの使用方法
BR0102252B1 (pt) 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
US6589938B2 (en) * 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US20050119180A1 (en) * 2002-03-28 2005-06-02 Roks Antonius J.M. Use of angiotensin 1-7 for enhancing cardiac function
BRPI0502497A (pt) 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
US7981867B2 (en) * 2005-09-09 2011-07-19 National University Of Singapore Use of des-aspartate-angiotensin I
BRPI0602366B1 (pt) 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
US8653031B2 (en) 2006-10-30 2014-02-18 Universidade Federal De Minas Gerais Process for the preparation of compositions of AT1 receptor antagonist and Angiotensin—(1-7)
ES2454741T3 (es) 2007-01-26 2014-04-11 Universidade Federal De Minas Gerais - Ufmg Composiciones farmac�uticas y m�todos para tratar la disfunci�n er�ctil
BRPI0800585B8 (pt) 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JANKOWSKI V ET AL.: "Mass-spectrometric identification of a novel angiotensin peptide in human plasma.", ARTERIOSCLER THROMB VASC BIOL., vol. 27, no. 2, February 2007 (2007-02-01), pages 297 - 302, XP008143376 *
SANTOS RA ET AL.: "Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas.", PROC NATL ACAD SCI U S A., vol. 100, no. 14, 8 July 2003 (2003-07-08), pages 8258 - 63, XP008133781 *
See also references of EP2264048A4 *

Also Published As

Publication number Publication date
US20130183367A1 (en) 2013-07-18
EP2264048A2 (en) 2010-12-22
CN102124023A (zh) 2011-07-13
WO2009100513A2 (pt) 2009-08-20
EP2264048A4 (en) 2011-11-16
BRPI0800585B1 (pt) 2019-10-22
BRPI0800585A2 (pt) 2010-12-28
US9974825B2 (en) 2018-05-22
BRPI0800585B8 (pt) 2021-05-25
EP2264048B1 (en) 2016-07-13

Similar Documents

Publication Publication Date Title
WO2009100513A3 (pt) Peptideo des-[asp1hala1]- agonista da angiotensina-(1 -7) e composiҫões farmacêuticas para tratamento de doenças
WO2008075376A8 (en) Polymorphic forms of bortezomib and process for their preparation
WO2006099379A3 (en) Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
MY161991A (en) Proteasome inhibitors
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
IL195142A (en) Processed arylaimidazolone and triazolone, their preparation process, pharmaceutical preparations containing them for the treatment or prevention of diseases
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
WO2007059905A3 (en) Thienopyrimidines treating inflammatory diseases
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
WO2007146284A3 (en) Thienopyrimidines useful as modulators of ion channels
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005000860A3 (en) Compositions and methods for treatment of disease with acetylated disaccharides
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009062576A3 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
CL2009001019A1 (es) Compuestos derivados de pirrolo[1,2-c]imidazol-3-ona, imidazo[indol-3-ona e imidazo[1,5-a]piridin-3-ona sustituidos; procedeimiento de preparacion; su composicion farmaceutica; utiles en el tratamiento de la diabetes, obesidad, trastornos de ingesta d comida o dislepidemia.
WO2009045992A3 (en) C-met protein kinase inhibitors
WO2009130615A3 (de) Verwendung von deuteriumoxid als elastase-inhibitor
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2010011994A3 (en) Polypeptides and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980108947.1

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009841273

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009841273

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09841273

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12867599

Country of ref document: US